Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).
this year under the U.S. Food and Drug Administration's accelerated pathway. Trial results later showed it slowed the rate of cognitive decline by 27% compared with a placebo in patients with early disease.
Most of the estimated 6 million Americans who have Alzheimer's receive their health coverage through Medicare. The cost of treating these patients "could strain the Medicare program and its beneficiaries, who may face rising premiums to help Medicare pay for the drug," Julia Cave Arbanas, research project manager and one of the paper’s lead authors, said in a statement.
Medicare estimates, published in JAMA Internal Medicine, found that out-of-pocket costs for patients lacking additional health insurance could reach $6,600 per year - about one-fifth of the median income for a Medicare beneficiary.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Whiffing menthol could snuff out symptoms of Alzheimer’s disease: studySmells can evoke strong memories — but a certain smell may even help hold onto them and ease the symptoms of Alzheimer’s.
Lire la suite »
Cook County couple, Chicago social worker charged in $1.16M Medicare fraud schemeA husband-and-wife team, along with a Chicago social worker, have been indicted for allegedly scheming to defraud Medicare of over $1.16 million.
Lire la suite »
Pfizer CEO says Medicare will likely face legal action over drug price negotiationsPfizer CEO Albert Bourla argued the Biden administration's plan will cut profits and force Big Pharma companies to pull back on developing medicines.
Lire la suite »
Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drugThe U.S. Food and Drug Administration approved Otsuka Pharmaceutical's brexpiprazole to treat agitation in patients with Alzheimer's on Thursday, making it the first approved drug for the indication, the company said in a statement.
Lire la suite »
Medscape Now! Hot Topics in Mental Health May 2023📍 Latest on MedscapeNow: Hot Topics in Mental Health for MentalHealthMonth. ➡️ Learn through novel studies that may have implications for the management of schizophrenia, suicide attempts, and Alzheimer’s disease by taking our activity. CME 📝 Learn:
Lire la suite »
FDA Approves First Drug to Treat Alzheimer's AgitationThe antipsychotic brexpiprazole (Rexulti) is the first FDA-approved treatment option for agitation associated with Alzheimer's disease.
Lire la suite »